AUTOIMMUNE RHEUMATIC DISEASES: RESULTS AND PROSPECTS FOR RESEARCHES
https://doi.org/10.14412/1995-4484-2015-230-237
Abstract
According to the present-day views, autoimmunity is a complex pathological process, the essence of which is intolerance and hence a pathological immune response to intrinsic tissue components (autoantigens), which underlies the pathogenesis of a broad spectrum of human autoimmune diseases. Recently, diverse immune disorders underlying autoimmune rheumatic diseases (ARD) and syndromes have been revealed; an association has been found between the development of ARD and autoinflammatory diseases and syndromes; a classification of human immunoinflammatory diseases has been elaborated. The paper considers the results of the authors’ investigations of ARD treatment with innovative biologics, the pathogenetic mechanisms and diagnosis of ARD, by conducting immunological and molecular biological studies of a wide range of molecular and cellular biomarkers (autoantibodies, acute phase proteins, cytokines, chemokines, vascular endothelial activation markers, complement system components, lymphocyte subpopulations, bone and cartilage tissue metabolic products, genetic, epigenetic, transcriptomic markers), and approaches to personalized treatment of ARD.
About the Authors
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
E. N. Aleksandrova
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
A. A. Novikov
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522
Russian Federation
Russian Federation
References
1. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med. 2006;(3):1242–8. doi: 10.1371/journal.pmed.0030297
2. Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290–331 [Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional'noe rukovodstvo [Rheumatology. National Guide]. Moscow: GEOTAR-Media; 2008. P. 290–331].
3. Goldblatt F, O’Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382:797–808. doi: 10.1016/S0140-6736(13)61499-3
4. Cho JH, Gregersen PK. Genomics and the multifactorial nature of human autoimmune disease. New Engl J Med. 2011;365:1612–23. doi: 10.1056/NEJMra1100030
5. Wahren-Herlenius M, Dorner T. Immunopathogenetic mechanisms of systemic autoimmune diseases. Lancet. 2013;382:819–31. doi: 10.1016/S0140-6736(13)60954-X
6. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. New Engl J Med. 2011;365:2205–19. doi: 10.1056/NEJMra1004965
7. Насонов ЕЛ, Александрова ЕН, Авдеева АС, Рубцов ЮП. Т-регуляторые клетки при ревматоидном артрите. Научно-практическая ревматология. 2014;52(4):430–7 [Nasonov EL, Aleksandrova EN, Avdeeva AS, Rubtsov YuP. T regulatory cells in rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(4):430–7 (In Russ.)]. doi: 10.14412/1995-4484-2014- 430-437
8. Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС, 2012; 344 с. [Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: a focus on rituximab]. Moscow: IMA-Press; 2013; 344 p.].
9. Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-Пресс; 2013; 552 с. [Nasonov EL, editor. Genno-inzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA-Press; 2013; 552 p.].
10. Murphy G, Lisnevskaia L, Isenberg D. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Lancet. 2013;382:809–18. doi: 10.1016/S0140- 6736(13)60889-2
11. Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of Rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575–80. doi: 10.1136/ard.2010.148759
12. Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in Rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71:374–7. doi: 10.1136/annrheumdis-2011-200003
13. Панасюк ЕЮ, Амирджанова ВН, Авдеева АС и др. Опыт применения тоцилизумаба у больных ревматоидным артритом (по данным многоцентрового исследования ЛОРНЕТ). Научно-практическая ревматология. 2013;51(2):104–10 [Panasyuk EYu, Amirdzhanova VN, Avdeeva AS, et al. Experience with tocilizumab in patients with heumatoid arthritis (according to the data of the LORNET multicenter trial). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):104–10 (In Russ.)].
14. Пчелинцева АО, Панасюк ЕЮ, Рябицева ОФ и др. Эффективность этанерцепта у больных ревматоидным артритом (результаты российского многоцентрового исследования ЭТАЛОН). Научно-практическая ревматология. 2013;51(6):639–45 [Pchelintseva AO, Panasyuk EYu, Ryabitseva OF, et al. Efficacy of etanercept in patients ith rheumatoid arthritis (results of the Russian multicenter ETALON study). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):639–45 (In Russ.)]. doi: 10.14412/1995-4484-2013-639-45
15. Pavelka K, Szekanecz Z, Damjanov N, et al. Induction of response with etanercept-methotrexate therapy in patients with moderate active rheumatoid arthritis in Central and Eastern Europe in the PRESERVE study. Clinical Rheumatol. 2013;32:1275–81. doi: 10.1007/s10067-013-2240-4
16. Smolen JS, Nash P, Durez P, et al. Maintenance, reduction or withdrawal of Etanercept: a randomized controlled trial in moderate rheumatoid arthritis patients achieving low disease activity with etanercept-methotrexate therapy. Lancet. 2013;381:918–29. doi: 10.1016/S0140-6736(12)61811-X
17. Каратеев ДЕ, Насонов ЕЛ, Денисов ЛН и др. Новые возможности терапии ревматоидного артрита: российский опыт применения цертолизумаба пэгол. Научно- практическая ревматология. 2012;50(2):14–9 [Karateev DE, Nasonov EL, Denisov LN, et al. New treatment possibilities for rheumatoid arthritis: The Russian experience in using certolizumab pegol. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(2):14–9 (In Russ.)].
18. Каратеев ДЕ, Насонов ЕЛ, Лучихина ЕЛ и др. Эффективность и безопасность лечения адалимумабом больных активным ревматоидным артритом с резистентностью к стандартной терапии: результаты Российского национального исследования. Терапевтический архив. 2012;(8):22–8 [Karateev DE, Nasonov EL, Luchikhina EL, et al. The efficacy and safety of treatment with adalimumab patients with active rheumatoid arthritis resistant to standard therapy: results of the Russian national study. Terapevticheskii arkhiv. 2012;(8):22–8 (In Russ.)].
19. Насонов ЕЛ, Каратеев ДЕ, Лукина ГВ. Фармакотерапия ревматоидного артрита в начале 21 века: российский и международный опыт. Терапевтический архив. 2013;(8):20–8 [Nasonov EL, Karateev DE, Lukina GV. Pharmacotherapy of rheumatoid arthritis in the early 21st century: Russian and international experience. Terapevticheskii arkhiv. 2013;(8):20–8 (In Russ.)].
20. Ананьева ЛП, Соловьев СК, Бекетова ТВ и др. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях: эффективность и переносимость у 229 больных. Научно-практическая ревматология. 2014;52(5):495–506 [Ananieva LP, Soloviyov SK, Beketova TV, et al. Anti-B-cell therapy at immune inflammatory rheumatic diseases: efficacy and tolerability in 229 patients. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(5):495–506 (In Russ.)]. doi: 10.14412/1995-4484-2014-495-506
21. Genovese MC, McKay JG, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–80. doi: 10.1002/art.23940
22. Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept. A phase IIIb non-inferiority study in patients with inadequate response to ethotrexate. Arthritis Rheum. 2011;63:2854–64. doi: 10.1002/art.30463
23. Genovese MC, Pachero Tena C, Covarrubias A, et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm Data from the ACQUIRE trial. J Rheumatol. 2014;41:629–39. doi: 10.3899/jrheum.130112
24. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31. doi: 10.1016/S0140-6736(10)61354-2
25. Smolen JS, Aletaha D, Bijsma JWJ, et al. For the T2T Expert Committee. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631–7. doi: 10.1136/ard.2009.123919
26. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492–509. doi: 10.1136/annrheumdis-2013-204573
27. Nasonov EL, Karateev DE. Does Russia need a treat-to-target initiative? Adopting a global strategy to improve outcome locally. Rheumatology (Oxford). 2015;54:381–2. doi: 10.1093/rheumatology/keu156
28. Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Рекомендации EULAR по лечению ревматоидного артрита – 2013: общая характеристика и дискуссионные проблемы. Научно- практическая ревматология. 2013;51(6):609–22 [Nasonov EL, Karateev DE, Chichasova NV. EULAR recommendations for the treatment of rheumatoid arthritis – 2013: general characteristics and disputable problems. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(6):609–22 (In Russ.)]. doi: 10.14412/1995-4484-2013-609-22
29. Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8–26 [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): the role of methotrexate. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):8–26 (In Russ.)]. doi: 10.14412/1995-4484-2014-8-26
30. Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117–25 [Karateev DE, Luchikhina EL, Murav'ev YuV, et al. The first Russian Strategic Study Of Pharmacotherapy For Rheumatoid Arthritis (REMARCA). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):117–25 (In Russ.)].
31. Каратеев ДЕ, Лучихина ЕЛ, Демидова НВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА): результаты ечения 130 больных в течение 12 месяцев. Научно-практическая ревматология. 2014;52(6):607–14 [Karateev DE, Luchikhina EL, Demidova NV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA trial): Results of 12-month treatment in 130 patients. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(6):607–14 (In Russ.)]. doi: 10.14412/1995-4484-2014-607-614
32. Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России – 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477–94 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 014;52(5):477–94 (In Russ.)]. doi: 10.14412/1995-4484-2014- 477-494
33. Насонов ЕЛ, Александрова ЕН. Современные технологии и перспективы лабораторной диагностики ревматических заболеваний. Терапевтический архив. 2010;(5):5–9 [Nasonov EL, Aleksandrova EN. Modern technologies and prospects of laboratory diagnosis of rheumatic diseases. Terapevticheskii arkhiv. 2010;(5):5–9 (In Russ.)].
34. Александрова ЕН, Новиков АА, Насонов ЕЛ. Современные стандарты лабораторной диагностики ревматических заболеваний и их применение в реальной клинической практике. Научно-практическая ревматология. 2013;51(4):368–76 [Aleksandrova EN, Novikov AA, Nasonov EL. The current standards for laboratory diagnosis of rheumatic diseases and their use in real clinical practice. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(4):368–76 (In Russ.)].
35. Tozzoli R, Bonaguri C, Melegari A, et al. Current state of diagnostic technologies in the autoimmunology laboratory. Clin Chem Lab Med. 2013;51:129–38. doi: 10.1515/cclm-2012-0191
36. Новиков АА, Александрова ЕН, Насонов ЕЛ. Протеомные исследования в ревматологии. Научно-практическая ревматология. 2012;50(6):19–24 [Novikov AA, Aleksandrova EN, Nasonov EL. Proteomic research in rheumatology. Nauchno- rakticheskaya revmatologiya = Rheumatology Science and Practice. 2012;50(6):19–24 (In Russ.)]. doi: 10.14412/1995-4484-2012-1295
37. Новиков АА, Александрова ЕН, Насонов ЕЛ. Создание и применение диагностического индекса, основанного на многопараметрическом анализе биомаркеров, для определения активности ревматоидного артрита. Научно-практическая ревматология. 2014;52(1):72–8 [Novikov AA, Aleksandrova EN, Nasonov EL. Elaboration and application of the diagnostic index based on multivariate analysis of iomarkers to determine the activity of rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):72–8 (In Russ.)]. doi: 10.14412/1995-4484-2014-72-8
38. Avdeeva AS, Aleksandrova EN, Novikov AA, et al. The relationship of antibodies to modified citrullinated vimentin and markers of bone and cartilage destruction in rheumatoid arthritis. Int J Rheumatol. 2014;2014:464585. doi: 10.1155/2014/464585. Epub 2014 Apr 15.
39. Shi J, van Veelen PA, Machler M, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmune Rev. 2014;13:225–30. doi: 10.1016/j.autrev.2013.10.008
40. Maksymowych WP, van der Heijde D, Allaart CF. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther. 2014;16:R99. doi: 10.1186/ar4547
41. Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013 Apr 9;8(4):e60635. doi: 10.1371/journal.pone.0060635. Print 2013.
42. Новиков АА, Александрова ЕН, Герасимов АН и др. Многопараметрический анализ биомаркеров в лабораторной диагностике раннего ревматоидного артрита. Научно- практическая ревматология. 2013;51(2):111–6 [Novikov AA, Aleksandrova EN, Gerasimov AN, et al. Multiparameter analysis of biomarkers in the laboratory diagnosis of early rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2013;51(2):111–6 (In Russ.)]. doi: 10.14412/1995-4484-2013-636
43. Насонов ЕЛ. Ревматоидный артрит: проблемы и значение персонифицированной медицины. Терапевтический архив. 2012;(5):5–9 [Nasonov EL. Rheumatoid arthritis: the problem and the importance of personalized medicine. Terapevticheskii arkhiv. 2012;(5):5–9 (In Russ.)].
44. Robinson WH, Lindstrom TM, Cheung RK, Sokolove J. Mechanistic biomarkers for clinical decision making in rheumatic diseases. Nat Rev Rheumatol. 2013;9:267–76. doi: 10.1038/nrrheum.2013.14
45. Авдеева АС, Александрова ЕН, Насонов ЕЛ. Клиническое значение матриксных металлопротеиназ при ревматоидном артрите (обзор литературы и собственные данные). Научно-практическая ревматология. 2014;52(1):79–84 [Avdeeva AS, Aleksandrova EN, Nasonov EL. The clinical significance of matrix metalloproteinases in rheumatoid arthritis patients (review of the literature and our own data). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(1):79–84 (In Russ.)]. doi: 10.14412/1995-4484-2014-79-84
46. Авдеева АС, Новиков АА, Александрова ЕН и др. Динамика уровней цитокинов на фоне терапии метотрексатом и адалимумабом у пациентов с ранним ревматоидным артритом (исследование РЕМАРКА). Научно-практическая ревматология. 2014;52(3):254–62 [Avdeeva AS, Novikov AA, Aleksandrova EN, et al. Changes of cytokine levels during therapy with methotrexate and adalimumab in patients with early rheumatoid
47. arthritis (REMARCA study). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014;52(3):254–263 (In Russ.)]. doi: 10.14412/1995-4484-2014-254-262
Review
For citations:
Nasonov E.L., Aleksandrova E.N., Novikov A.A. AUTOIMMUNE RHEUMATIC DISEASES: RESULTS AND PROSPECTS FOR RESEARCHES. Rheumatology Science and Practice. 2015;53(3):230-237. (In Russ.) https://doi.org/10.14412/1995-4484-2015-230-237
Views:
3616
Email this article 